Gapping down
In reaction to earnings/guidance:
- SCHL -4.4%, COST -3.2%, APEI -1.3%
Select ETFs showing early weakness:
- USO -3.2%, SLV -2.8%, IWM -1.6%, GLD -1.5%, QQQ -1.4%, SPY -1.3%, DIA -1.2%
Other news:
- EDAP -11.3% (prices offering of 2,666,667 ADSs at $7.50 per ADS)
- AORT -8.1% (follows recommendation to stop PROACT Xa Clinical Trial)
- RIOT -6.9% (supplementing its disclosures regarding the material weaknesses identified by management)
- AZN -3.6% (AstraZeneca partner Ionis Pharma provides update on development program evaluating PCSK9 antisense medicine; ION449 will not advance into Phase 3 development based on pre-specified criteria)
- IONS -3.3% (Ionis Pharma provides update on development program evaluating PCSK9 antisense medicine; ION449 will not advance into Phase 3 development based on pre-specified criteria)
- MOS -3.1% (reports August revs and sales volumes)
- DIBS -2.9% (announces 10% workforce reduction)
- ROKU -2.6% (names three senior execs as presidents)
- DOCU -2.4% (names Google exec Allan Thygesen as CEO)
- BLDP -2.4% (receives order for 14 x 200 kW fuel cell modules from Siemens Mobility)
- BJ -2.3% (in sympathy with COST earnings)
- BA -2.3% (to pay $200 mln to settle case with SEC relating to former CEO misleading statements re 737 MAX)
- KSS -2% (activist investor Ancora favors Tom Kingsbury as CEO replacement, according to Axios)
- FTI -1.9% (wins Shell contract worth $75-250 mln for Jackdaw development in the UK)
- QCOM -1.8% (automotive design-win pipeline has grown to $30 bln)
- PVH -1.5% (names new Chief Strategy Officer)
- TGT -1.5% (in sympathy with COST earnings)
Analyst comments:
- ALLY -2.8% (downgraded to Equal Weight from Overweight at Wells Fargo)
- DLR -2.5% (downgraded to Underweight from Equal Weight at Barclays)
- EQIX -1.5% (downgraded to Equal Weight from Overweight at Barclays)